Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification of robust predictors for ibrutinib response by multiomics in MYD88-mutated Waldenström macroglobulinemia.
Richardson K, Castillo JJ, Sarosiek SR, Branagan AR, Flynn CA, Meid K, Gustine JN, Liu X, Kofides A, Liu S, Wolf JL, Kacena KA, Patterson CJ, Guerrera ML, Tsakmaklis N, Treon SP, Hunter ZR. Richardson K, et al. Among authors: flynn ca. Blood Adv. 2024 May 14;8(9):2133-2137. doi: 10.1182/bloodadvances.2023012111. Blood Adv. 2024. PMID: 38237078 Free PMC article. No abstract available.
Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia.
Castillo JJ, Branagan AR, Sermer D, Flynn CA, Meid K, Little M, Stockman K, White T, Canning A, Guerrera ML, Kofides A, Liu S, Liu X, Richardson K, Tsakmaklis N, Patterson CJ, Hunter ZR, Treon SP, Sarosiek S. Castillo JJ, et al. Among authors: flynn ca. Blood. 2024 Feb 15;143(7):582-591. doi: 10.1182/blood.2023022420. Blood. 2024. PMID: 37971194 Free PMC article.
A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas.
Munshi M, Liu X, Kofides A, Tsakmaklis N, Guerrera ML, Hunter ZR, Palomba ML, Argyropoulos KV, Patterson CJ, Canning AG, Meid K, Gustine J, Branagan AR, Flynn CA, Sarosiek S, Castillo JJ, Wang J, Buhrlage SJ, Gray NS, Munshi NC, Anderson KC, Treon SP, Yang G. Munshi M, et al. Among authors: flynn ca. Blood Adv. 2022 Jun 14;6(11):3332-3338. doi: 10.1182/bloodadvances.2021006147. Blood Adv. 2022. PMID: 35255496 Free PMC article.
Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy.
Castillo JJ, Sarosiek SR, Gustine JN, Flynn CA, Leventoff CR, White TP, Meid K, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, Hunter ZR, Patterson CJ, Branagan AR, Treon SP. Castillo JJ, et al. Among authors: flynn ca. Blood Adv. 2022 Feb 8;6(3):1015-1024. doi: 10.1182/bloodadvances.2021006106. Blood Adv. 2022. PMID: 34965304 Free PMC article.
Venetoclax in Previously Treated Waldenström Macroglobulinemia.
Castillo JJ, Allan JN, Siddiqi T, Advani RH, Meid K, Leventoff C, White TP, Flynn CA, Sarosiek S, Branagan AR, Demos MG, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, Xu L, Yang G, Patterson CJ, Hunter ZR, Davids MS, Furman RR, Treon SP. Castillo JJ, et al. Among authors: flynn ca. J Clin Oncol. 2022 Jan 1;40(1):63-71. doi: 10.1200/JCO.21.01194. Epub 2021 Nov 18. J Clin Oncol. 2022. PMID: 34793256 Free PMC article. Clinical Trial.
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia.
Castillo JJ, Meid K, Gustine JN, Leventoff C, White T, Flynn CA, Sarosiek S, Demos MG, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, Xu L, Yang G, Branagan AR, O'Donnell E, Raje N, Yee AJ, Patterson CJ, Hunter ZR, Treon SP. Castillo JJ, et al. Among authors: flynn ca. Leukemia. 2022 Feb;36(2):532-539. doi: 10.1038/s41375-021-01417-9. Epub 2021 Sep 16. Leukemia. 2022. PMID: 34531537 Free PMC article.
60 results